Navigation Links
Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
Date:9/24/2010

TAMPA, Fla. Moffitt Cancer Center and GLG Pharma, LLC announced today that they have entered into a licensing agreement under which GLG Pharma, LLC has acquired the exclusive worldwide rights to a technology platform that includes a series of STAT3 inhibitors. Researchers at Moffitt discovered several classes of STAT3 inhibitors and evaluated their potential pre-clinically as novel anti-cancer drugs.

"Persistently activated STAT3 is a major contributor to human cancer; validating its usefulness as a cancer therapeutic target in collaboration with GLG will be a major milestone," said Said Sebti, Ph.D., chair of the Drug Discovery Department at Moffitt.

"One of several recent startup companies to be based on Moffitt technologies, GLG brings a highly experienced management team to the mix," said Ray Carpenter, senior licensing manager of The Office of Technology Management and Commercialization at Moffitt. "Their combined experience in taking technologies through clinical trials instills confidence that these technologies surrounding an important target, like the STAT3 pathway, is being placed in capable hands. Our office is delighted that GLG Pharma will move this technology from the laboratory to the clinic to improve patient care."

Under the license agreement, GLG Pharma has agreed to pay Moffitt when various commercialization milestones are reached, as well as make royalty payments on the sales of testing services and licensed products.

"This license agreement is the first key milestone established for the company in 2010," said Hector J. Gomez, M.D., Ph.D., CEO of GLG Pharma. "We believe that STAT3 inhibitors are the next generation of targeted therapies. They are anticipated to be very specific, have a broad spectrum of activity and are expected to be well tolerated and more efficacious compounds than current therapies."


'/>"/>

Contact: Michelle Foley
MFoley@Moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Cancer-associated long noncoding RNA regulates pre-mRNA splicing
3. Declining breast cancer incidence in Canada with declining HRT usage
4. Sexual Problems May Arise After Breast Cancer
5. UCLA cancer researchers discover new signaling pathway that controls cell development and cancer
6. Patients with cancer who stop hospice care boost health-care costs
7. Mammograms Cut Breast Cancer Death Rates, But Only Modestly: Study
8. David Cheresh receives top award for cancer metastasis research
9. 70 percent of women likely to experience sexual problems after breast cancer
10. Physical limitations of breast cancer survivors
11. Synthetic lethality strategy improves molecularly targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... 25, 2014 Recently, BellasDress ... all its wedding dresses. BellasDress has chosen their best-selling ... gift choices for the holiday season. , Now, ... suitable wedding gowns here at discount prices. The business ... at its website. , “All our elegant ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Blue Distinction ... of the Blue Cross and Blue Shield Association,s expansion of its Blue Distinction® designation. ... Abington, PA (Vocus) February 18, ... a Blue Distinction Center for Spine Surgery and as a Blue Distinction Center for Knee ...
... ... Convert2XHTML.com offers a full range of PSD to XHTML / PSD to HTML / CSS ... for open source content management engines (Joomla, Drupal, etc). , ... Charlotte, USA (PRWEB) February 18, 2010 -- Convert2xhtml.com introduces separate ...
... The free Bible ... entitled God,s New Law, which describes a prophecy from the year 2000 that forgives homosexuality and ... gay marriage in God,s kingdom. , ... San Diego, CA (PRWEB) February 18, 2010 -- This is a new version of the Holy ...
... ... an online Private Label capability to build their brand and enhance the agility of their ... ... is introducing a new capability for Chief Learning Officers to deliver their organization,s brand ...
... ... and Ensure Data Privacy and Security Regulations under HITECH Compliance , ... Scottsdale, Ariz. (PRWEB) February 18, 2010 ... a policy in place to limit disclosure of Protected Health Information (PHI), yet only ...
... , , SAN FRANCISCO , ... TBR-652, which is being developed by Tobira Therapeutics for ... between drug exposure and viral suppression with this next-generation ... at the 17th Conference on Retroviruses and Opportunistic Infections ...
Cached Medicine News:Health News:Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM) 2Health News:Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM) 3Health News:Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM) 4Health News:Convert2XHTML.com Now Introduces Separate Team for Quality Check and Internal Audit to Improve Quality PSD to HTML Conversion 2Health News:Convert2XHTML.com Now Introduces Separate Team for Quality Check and Internal Audit to Improve Quality PSD to HTML Conversion 3Health News:Lo Cest Offers a Free Download of a New Bible for the Gay Community 2Health News:Agility Consulting Partners with pan (Performance Assessment Network) to Bring Custom Private Label Assessment Capability to Human Resource Professionals and Consultants 2Health News:New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 2Health News:New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 3Health News:Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobira's Next-Generation CCR5 Receptor Antagonist 2Health News:Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobira's Next-Generation CCR5 Receptor Antagonist 3
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... infringement action against Chinese medical device manufacturer BMC Medical Co., ... today that BMC,s masks listed below infringe ResMed,s patents, and ... these masks in the United States : ... nasal mask , Willow nasal pillows mask , ...
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Latest Randomized Clinical Trial Results of First Pro-Healing Stent Also ... ... OrbusNeich,s Genous(TM),Bio-engineered R stent(TM) is the subject of several ... year,s Transcatheter Cardiovascular Therapeutics symposium, TCT 2007,which is set for ...
... StatSure,Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) ... from Inverness Medical Innovations, Inc.,(Amex: IMA ... and Inverness,signed two additional agreements. First, the ... an option to the exclusive, worldwide,marketing and ...
Cached Medicine Technology:OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007 2StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations 2StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations 3
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: